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If we believe, as many of us do, that the industtywill indeed 
realize significant future sales of biotechnology products, we 
can then place a future value on these biotechnology compan-
ies in the conventional way in which we evaluate any industty 
group, such as the major pharmaceutical and drug sectors. We 
assume that not all future biotechnology product sales will be 
by these up-start start-ups-perhaps 50% would be a fair 
estimate. The balance of biotechnology product sales would 
be by the multi-national pharmaceutical and drug companies. 
Remember also that these large companies are acquiring, or 
investing in, these small biotechnology companies. 
Another point should be made. Although new biotechnol-
ogy companies will continue to start-up to exploit niche 
markets and specific product opportunity areas, the main-
stream of biotechnology companies will already have been 
established in the markets and new entries will be few. It is 
expected that fully 2/ 3 of the companies presently in business 
today will be gone in 10 years-some will fail , many will be 
acquired by others. As a result, a smaller number of companies 
will cut up the biotechnology pie in the future markets. 
The market value of the biotechnology companies (today 
$9 billion) may possibly be $100 bill ion in the year 2000- but 
divided among considerably fewer players. Assuming 50 bio-
technology companies remain at that time, the average market 
value of each company would be $2 billion-a 20-fold 
increase over the average market value today. 
Investment Strategies 
Before reaching for your checkbook to make an investment 
in biotechnology today, understand that any number of 
assumptions can be made and any number of differing results 
may be suggested. An investment today in evety one of the 
biotechnology companies held until the year 2000, quite 
assuredly will not realize the 20-fold average increase sug-
gested above. Even if the industty values came true in that 
year, dilution of the investment interests by the significant 
additions to equity capital that may be necessary along the way 
would change the returns. And how much is won or lost in 
those companies that are acquired or go out of business is 
anyone's guess. 
The hint of signficant values in biotechnology, however, is 
realistic. It may require considerable patience, some anguish, 
and a lot of luck, however, to realize your investment return 
dream in biotechnology. 
The typical investment strategies can be suggested. This 
assumes considerable diligence on your part, a lot of sound 
advice from others, and a long-term investment posture. 
Invest in those undervalued biotechnology companies that 
have significant technologies and markets, excellent man-
agement, considerable capital, several corporate partner rela-
tionships, and various sales and marketing agreements that 
will result in significant growth in sales and earnings. 
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Until comparatively recently, biotechnology has been a 
subject of intense interest to a relatively narrow audience, 
namely, to that segment of the scientific community working 
at the leading edge of this "new biology." While there has 
been a growing amount of communication in the lay press of 
the progress and implications of biotechnology, attempts to 
convey the significance of recombinant DNA, monoclonal 
antibodies, hybridoma cells, and DNA probes have been a bit 
bewildering to the general reader. This bewilderment has 
only been compounded by discussions of high-potential new 
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products with esoteric sounding names and strange sets of 
initials ; e.g. , tissue plasminogen activator (TPA) , tissue necro-
sis factor (TNF), colony stimulating factor ( CSF), epidermal 
growth factor (EGF), angiogenesis inhibitor, and Factor VIII, 
being pursued by a great number of new companies with 
confusingly similar names such as Genentech, Genex, Inte-
grated Genetics, Plant Genetics, Molecular Genetics, Biogen, 
Amgen, and Calgene. Excitement has nonetheless grown as 
the potential to employ this technology and these substances 
to treat diseases such as cancer, AIDS, and cardiovascular 
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disease has come into increasingly sharp focus. Along with 
this increasing awareness of a major new technology and 
major new business in the making, has come a growth in 
interest in the corresponding investment opportunities avail-
able. 
While it is always dangerous to make dogmatic assertions, 
there can be no doubt that biotechnology is destined to be big 
business. The products of this technology will revolutionize 
agricultural, veterinary, healthcare, chemical, energy, and 
waste management businesses, to name a few. However, 
while one can make a safe bet on this proposition, it does not 
follow that equally certain investment returns will result from 
a bet on any particular participant, or group of participants, in 
this emerging industry. The technology is very dynamic, and is 
being pursued by a large and growing number of companies. 
Some of these companies will fail , others will succeed-either 
on their own or by virtue of being acquired by others. In 
targeting particular companies as investment options, one 
needs to make judgments about company management, 
financial underpinning, technology, markets, marketing cap-
ability, manufacturing capability, patent position, regulatory 
requirements, competition, and strength of corporate 
partners. Even if one appropriately judges this multiplicity of 
key success factors and identifies a number of companies 
which, in fact, ultimately emerge as business successes, an 
investment in the common stock of one or more of these 
companies could still bring the investor to grief. 
In making common stock investments, it is important to 
view the stock as having a life of its own apart from the health 
and life of the underlying business. Thus, a company's busi-
ness may be doing very well, with excellent prospects for 
future sales and profit growth. Investors, sensing these pros-
pects, will generally bid the stock of such a company to levels 
at which an acceptable investment return is difficult to 
achieve. Subsequent reports of sales and earnings progress 
may be greatly improved over prior periods, but because such 
progress is less than anticipated, the stock declines in price. 
Conversely, a company's business may be experiencing some 
temporary hard times. But because investors are not certain 
whether, in fact, such times are temporary, or, even if tempor-
ary, how severe the hard times will be, the stock may be selling 
at such a discount to "fair value" that an investment made in 
the company's common stock yields excellent returns. Subse-
quent financial reports may show that the hard times are over 
sooner than expected and/ or are less severe than anticipated, 
leading to a price rise in the common stock. Thus, it often 
happens that when a company's business looks the worst, the 
common stock is at a price that subsequently proves to have 
been very attractive. Yet, this is also the point at which the 
psychological frame of mind of most investors is least dis-
posed to undertake investment risk. Again, it is important at 
any point to make separate judgments about the business and 
the stock. They do not often move in lockstep. 
The importance of rigorously separating the judgment of 
business prospects from that of stock valuation is even more 
important in the case of biotechnology, an emerging industry 
populated with emerging growth companies. Few of these 
companies have any significant product revenue at this point, 
and even fewer-you can count them on one hand-are 
profitable. The stocks of these companies tend to be "expecta-
tions" driven and "key milestone achievement" driven, rather 
than current, or even near-term, earnings driven. Since expec-
tations are frequently limited by very little more than our 
imaginations (or our greed), the stock of a company investi-
gating a cancer cure, or an AIDS vaccine, or an agent to abort 
heart attacks, is frequently bid up to levels difficult to main-
Volume 53, Number 1, 1987/ 88 
tain, or justify, even in the face of progress towards the 
expected goal. 
I will attempt to illustrate my point with an example. Amgen 
is considered to be one of the premier biotechnology com-
panies, one of the elite group of biotechnology companies 
voted by most knowledgeable observers as "most likely to 
succeed," a judgment with which I have absolutely no reason 
to disagree. As this is written, Amgen common stock is selling 
at $37 per share and the company has 16.3 million shares 
outstanding. In fiscal1986, the company had $23.4 million in 
total revenue-$20.2 million from corporate partners in sup-
port of Amgen R&D programs, $2.3 million in interest income 
from its cash, and a mere $0.86 million in product revenue. 
The company was profitable, earning $548,000, or $0.05 per 
share, although it clearly would not have been had it relied on 
profitable operations stemming from product revenue. I do 
not follow the company closely, but the consensus earnings 
estimate of 12 analysts who do, is that the company will earn 
$0.08 per share in fiscal1987. Thus, the stock is selling at 463 
times 1987 earnings. Considering that the overall market is 
currently selling at 15-16 times anticipated 1987 earnings, the 
current price of Amgen stock incorporates a considerable 
measure of assumed future success. As the industry and 
Amgen matures, this earnings multiple is going to decline. 
Let's just assume for the moment that Amgen was currently a 
solidly established business, with good, and growing, revenue 
and profits. Where should the company be in terms of revenue 
and profits to justify a multiple of 25 times earnings, still a 
near-70% premium to the market? Since the stock is selling at 
$37, a multiple of25 times earnings would imply earnings of 
37/ 25, or $1.48 per share. Given that the company currently 
has 16.3 million shares outstanding, $1.48 per share would 
dictate $24.1 million in net income. If we then assume that this 
net income amounts to a generous 15% of revenue, revenue 
would need to be more than $160 million, considerably 
greater than the $0.86 million achieved in fiscal 1986. 
I would emphasize that the point of this example is not that 
Amgen will never achieve $160 million in revenue; I have 
every reason to believe that it will. It is also not the point that 
Amgen common stock is not a good buy; I suspect that it will 
prove to be a good investment, particularly for investors who 
approach investing in such situations appropriately, a subject I 
will return to in a moment. Rather the point is that the prices of 
the expectations-driven stocks of emerging growth compan-
ies are subject to continuous, and frequently substantial, read-
justment, reflecting investor reaction to the real or imagined 
impact of events on the previously assumed level of ultimate 
success. Some of these events will be completely beyond the 
company's control as, for example, a time of overall reduced 
interest in the biotechnology sector of the market; a pro-
nounced overall bear market, wherein it is difficult for the 
stocks of any company to do well regardless of progress or 
prospects; the entrance of a competitor into the same markets; 
or a delay in receiving necessary regulatory approval for a 
.product. Any such events can lead investors to be, at least 
momentarily, less optimistic and less willing to pay the same 
price for the stock. The bottom line result with respect to 
investors is that emerging growth stocks tend to be highly 
volatile. Investors, particularly individual investors, frequently 
do poorly in such stocks because they lose their nerve and the 
courage of their convictions, selling out their positions at a 
loss. As mentioned earlier, this is frequently the time at which 
such stocks should be bought. Not always, however! 
If it seems that I am making every effort to scare potential 
biotechnology investors, let me emphasize my belief that 
excellent returns are available to investors who invest wisely 
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in this area. Since most people grasp very quickly the concept 
of exceptional return, but less quickly the concept of com-
mensurate exceptional risk-and risk and return do go hand 
in hand-I intentionally spend more time discussing risk. 
How should a person go about approaching investments in 
the biotechnology area, and what are the options? The first 
rule, important in any stock market investing, but particularly 
important with emerging growth stock investing, is not to 
venture any money that you cannot afford to have experience 
substantial erosion. As mentioned, growth stocks generally 
evince considerable volatility. Hence, you should not invest 
$5,000 absolutely needed six months from now for a child's 
college tuition payment. While the $5,000 could appreciate to 
$10,000 three years from now, it could just as easily depreciate 
to $2,500 in six months' time. While this first point is a rule, the 
second point is a suggestion. The suggestion is that once you 
have done adequate research to determine that the stock of 
"Biotech Company X" is an attractive buy, determine how 
much money you are prepared to invest/ risk, then commit 
some fraction of that, say 1/ 3 or 1/2. Then resolve to commit 
the other half (or another third as the case may be) when and 
if the price goes against you by a predetermined amount. If the 
stock moves up and away from you, be satisfied with how 
smart you were, rather than despairing over not having com-
mitted everything originally. If events subsequent to your 
original investment provide added confirmation for your 
assessment of the business and the stock, buy more stock at 
higher prices. If, on the other hand, the stock declines to your 
predetermined price points, and you are confident that the 
rationale for making your original investment is still intact, 
buy some more stock and average down in anticipation of the 
upward price move you expect. So much for strategy. What are 
the investment options? 
One investment option is to buy the stock of a "pure play" 
biotechnology company, a company whose future success is 
entirely dependent on its commitment to biotechnology. 
Depending on how you choose to count and characterize 
biotechnology companies, there are now at least 50 with 
publicly traded stock, with many others that are likely to come 
public in the days ahead. Many of these companies are nearly 
totally dedicated to therapeutic or pharmaceutical applica-
tions of biotechnology, others to diagnostic applications, 
some to agricultural and/ or veterinary applications, and still 
others to chemical, energy, or other industrial applications. 
Some companies have strong commitments to more than one 
of these areas of application. A partial, and clearly incomplete, 
list of companies considered to be at the forefront of their 
particular areas would include Amgen, Calgene, Centocor, 
Cetus, Chiron, Genentech, Genetics Institute, and Integrated 
Genetics. Sources of information on companies of interest 
would include the recent annual reports and quarterly reports 
(readily obtainable directly from the investor relations 
department of the company), analyst reports on the company 
(obtainable through a brokerage firm), and a good business 
library such as the JJ. Hill Reference Library in St. Paul. Such 
libraries generally contain numerous investment resources 
including The Wall Street Transcript, which carries a lengthy 
"Roundtable" discussion of the biotechnology industry at 
least once a year. 
The so-called "pure play" investment option carries the 
potential for the greatest -even spectacular -returns of any of 
the investment options to be discussed, assuming one "bets 
on the right horse." This option also carries the potential of 
the greatest- approaching total-loss, if you select poorly. 
The "pure play, all the eggs in one basket" approach entails 
both the prospects of exceptional return and exceptional risk. 
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A second approach would be to attempt to reduce potential 
risk, although at the same time reducing potential return, by 
taking an individual diversification approach. That is to say, 
rather than investing a given sum in one biotechnology stock, 
invest, for example, one-third of that sum in each of three 
biotechnology stocks. Assuming that you have done reason-
ably good homework, it is not likely that all the selections will 
perform dismally, although it is also unlikely that all will 
perform spectacularly. One excellent choice can still mask the 
"sins" of two poor to mediocre performers, yielding overall 
good investment returns. You should stay mindful that while 
this individual diversification approach can insulate you 
somewhat from issue-specific investment risk, it does not 
provide protection from overall market risk. As mentioned 
earlier, it is difficult to find any stocks that go up in the midst of 
a strong overall bear market. In fact , in such a market, emerg-
ing growth stocks with high levels of assumed future success 
incorporated into their stock prices tend to be the most 
vulnerable. 
A third biotechnology investment option would be what 
can be called the "single stock diversification" approach. What 
is suggested here is to select common stocks of companies 
that are successfully established in existing businesses but 
that seek to enlarge those businesses or to establish new 
businesses through the application ofbiotechnology. Illustra-
tive examples could include Abbott laboratories, Eli Lilly, 
Bristol-Myers, Merck, Syntex, Johnson & Johnson, Becton 
Dickinson, and (surprise!) Eastman Kodak. 
The so-called single stock diversification approach would 
be expected to reduce risk significantly. In the case of Abbott 
laboratories, for example, this company is clearly well estab-
lished, a near "blue chip," with leadership positions in phar-
maceutical, diagnostic, and hospital supply businesses. Both 
the Abbott business and the common stock have been solid 
performers for years. The company is making substantial 
investments in biotechnology, both within its own research 
laboratories as well as through the support of research pro-
grams in the laboratories of various "pure play" biotechnol-
ogy companies. Should this "drilling" for new biotech pro-
ducts strike a "dry hole," the base of solidly established 
businesses with good performances would substantially 
cushion the company and its investors. Conversely, a spectac-
ularly successful new biotechnology product would not have 
the same positive impact on the financial performance of an 
Abbott Laboratories that it would have on a smaller, "pure 
play" company. The financial impact on a company the size of 
Abbott would be less, with a correspondingly reduced impact 
on the price of the stock, as well as on investor return. Again, if 
you insist on taking less risk, you should correspondingly 
reduce your return expectations. 
The fourth , and final , approach to investing in biotechnology 
is to turn over your money to a professional money manager 
who is committed to investing in biotechnology stocks, 
i.e., a biotechnology mutual fund. To a certain extent, this 
particular option is more conceptual than real , since I am not 
aware of the existence of a mutual fund devoted exclusively to 
biotechnology. In time there probably will be. The closest you 
would come would be through a fund such as the H&Q 
Healthcare Investors Fund, a fund committed to investing 
primarily in biotechnology, diagnostics, healthcare services, 
and pharmaceutical stocks. If the diagnostics and pharmaceut-
ical stocks selected for the Fund turn out to be companies 
seeking to achieve their business objective through biotech-
nology, this could approximate a pure biotechnology fund. In 
addition, this fund is committed to investing approximately 
25% of its cash in venture capital situations, a very high return/ 
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high risk approach rarely available to most people on an 
individual basis. The mutual fund approach offers a much 
more diversified, risk-reduced approach than is achievable via 
the previously mentioned individual diversification approach. 
However, I would again emphasize that in a strong bear 
market, even an investment in a large universe of stocks, each 
of which is itself high risk, is vulnerable. 
To summarize, efore choosing to invest in any common 
stocks, but particularly volatile, potential high risk/ high 
return, emerging growth stocks such as biotechnology stocks, 
"know thyself. " Know what you are prepared to risk, and how 
much risk you are prepared to take. Do not risk more than you 
are prepared to lose. Second, do your homework. Third, 
should you choose to invest in biotechnology stocks, choose 
an approach, be it the "pure play" or the three forms of 
diversification strategy, which most closely matches your risk 
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tolerance, while bearing in mind that diversification among a 
universe made up solely of high fisk stocks can only achieve 
so much risk reduction ; a certain return with essentially zero 
risk is obtainable only through U.S. Treasury bills. Fourth, 
once you have committed your hard-earned cash to the 
market, keep an open mind and a cool head-an open mind 
ready, willing, and able to continuously assess the impact of 
new information on original investment assumptions, and a 
cool head able to stay with an originally determined invest-
ment strategy as long as no new contrary information has 
come to light. Fifth, specific company names used during the 
course of these remarks are not intended nor should they be 
taken as investment recommendations, but rather as illustra-
tive examples and as places to begin making your own 
assessment. 
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